No article text was recorded for this version.
predictive biomarker identification
Version 1 of 158 papers59 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Targeting epigenetic regulators for cancer therapy
- Blog: An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma
- Blog: Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy
- Blog: Genomic and immunogenomic analysis of three prognostic signature genes in LUAD
- Blog: Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
- Blog: KLF4 loss in hepatocellular carcinoma: Improving prognostic prediction and correlating immune infiltrates
- Blog: Mitochondrial Homeostasis–Related lncRNAs are Potential Biomarkers for Predicting Prognosis and Immune Response in Lung Adenocarcinoma
- Blog: Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases
- Blog: Maximizing Efficacy of Cancer Nanovaccines and Immune Cells Landscape in Responders and Non‐Responders to Immunotherapy
- Blog: ICOSLG-associated immunological landscape and diagnostic value in oral squamous cell carcinoma: a prospective cohort study
- Blog: Allergen Immunotherapy (AIT): a prototype of Precision Medicine
- Blog: The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification
- Blog: Tumoral ALOX5 mediated arachidonic acid metabolism regulates immune response in non-small cell lung cancer
- Blog: Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer
- Blog: I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment
- Blog: Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
- Blog: Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
- Blog: The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer
- Blog: CD74 is a potential biomarker predicting the response to immune checkpoint blockade
- Blog: High Numbers and Densities of PD1+ T-Follicular Helper Cells in Triple-Negative Breast Cancer Draining Lymph Nodes Are Associated with Lower Survival
- Blog: Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
- Blog: New antibody approaches to lymphoma therapy
- Blog: Prognosis and immunological characteristics of HDAC family in pan-cancer through integrative multi-omic analysis
- Blog: Potential role of P4HB in the tumor microenvironment and its clinical prognostic value: a comprehensive pan-cancer analysis and experimental validation with a focus on KIRC
- Blog: A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
- Blog: An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas
- Blog: TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
- Blog: Novel six-gene prognostic signature based on colon adenocarcinoma immune-related genes
- Blog: Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
- Blog: <b>The mechanism of high-frequency rTMS </b><b>for intractable pain, a TMS study </b>
- Blog: The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders
- Blog: Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes
- Blog: The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors
- Blog: Deep immunophenotyping reveals clinically distinct cellular states and ecosystems in large-scale colorectal cancer
- Blog: Comprehensive Analysis of a Novel Immune-Related Gene Signature in Lung Adenocarcinoma
- Blog: Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1
- Blog: PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
- Blog: Influence of Prone Position on the Survival of COVID-19 Patients Undergoing Invasive Mechanical Ventilation: A Propensity Score Matching Study
- Blog: Combined Inhibition of IAPs and WEE1 Enhances TNFα- and Radiation-Induced Cell Death in Head and Neck Squamous Carcinoma
- Blog: Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
- Blog: Diagnosis and functional prediction of microbial markers in tumor tissues of sporadic colorectal cancer patients associated with the MLH1 protein phenotype
- Blog: An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles
- Blog: PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy
- Blog: Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development
- Blog: Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
- Blog: Unveiling the Prognostic Power and Immune Landscape of MyD88 in Breast Cancer: an Integrative Bioinformatics and IHC Approach
- Blog: Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma
- Blog: Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer
- Blog: Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
- Blog: LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
- Blog: Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine
- Blog: Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer
- Blog: Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer
- Blog: Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma
- Blog: Re-Clustering and Profiling of Digestive System Tumors According to Microenvironment Components
- Blog: A predictive radiotranscriptomics model based on DCE-MRI for tumor immune landscape and immunotherapy in cholangiocarcinoma
- Blog: 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
- Blog: Identification of N6-Methylandenosine-Related lncRNAs for Subtype Identification and Risk Stratification in Gastric Adenocarcinoma
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_predictive_biomarker_identification_472a5db4,
title = {predictive biomarker identification},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/predictive-biomarker-identification/rdr_472a5db4dd1c41cfaa8b0286a8c3f3e3},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_predictive_biomarker_identification_472a5db4_v1,
title = {predictive biomarker identification},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/predictive-biomarker-identification/rdr_472a5db4dd1c41cfaa8b0286a8c3f3e3/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}